Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 5/2020

01-10-2020 | Hepatitis B | Case Report

Spontaneous reactivation of hepatitis B virus with S gene mutations in an elderly patient with diabetic nephropathy

Authors: Noriyuki Obara, Jun Inoue, Hiroyuki Endo, Eiji Kakazu, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano, Mio Tsuruoka, Atsushi Masamune

Published in: Clinical Journal of Gastroenterology | Issue 5/2020

Login to get access

Abstract

Generally, reactivation of hepatitis B virus (HBV) infection is induced by the administration of immunosuppressants or anticancer agents, but reactivation without such drugs has rarely been reported. Here we report an elder case with spontaneous reactivation of HBV replication accompanied by hepatitis B surface antigen (HBsAg) mutations. A 69-year-old man with a history of diabetes mellitus and chronic kidney disease (CKD) was found to be positive for HBsAg (0.072 IU/ml) in June 2018. In May 2019, marked hepatic dysfunction and increased HBsAg (2533.2 IU/ml) were observed when he visited the hospital due to diarrhea and worsening of CKD. At that time, hepatitis B surface antibody (HBsAb) was positive (268.9 mIU/ml) and HBV DNA was 6.0 log IU/ml. After treatment with entecavir, HBV DNA and HBsAg rapidly decreased. Full-genome HBV sequence analysis revealed that the patient was infected with HBV of subgenotype B1 and it had an “a” determinant mutation M133L in the S gene coding HBsAg. Notably, both HBsAg and HBsAb were positive at the time of HBV reactivation, suggesting that the HBV with these mutations escaped from neutralization by HBsAb. This case suggests that immune escape mutations could play an important role in spontaneous HBV reactivation.
Literature
1.
go back to reference Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRef Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRef
2.
go back to reference Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–S165165.CrossRef Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–S165165.CrossRef
3.
go back to reference Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRef Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRef
4.
go back to reference Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.CrossRef Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.CrossRef
5.
go back to reference Inoue J, Nakamura T, Masamune A. Roles of hepatitis B virus mutations in the viral reactivation after immunosuppression therapies. Viruses. 2019;11:457.CrossRef Inoue J, Nakamura T, Masamune A. Roles of hepatitis B virus mutations in the viral reactivation after immunosuppression therapies. Viruses. 2019;11:457.CrossRef
6.
go back to reference Inoue J, Kondo Y, Wakui Y, et al. Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy. Clin J Gastroenterol. 2016;9:93–8.CrossRef Inoue J, Kondo Y, Wakui Y, et al. Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy. Clin J Gastroenterol. 2016;9:93–8.CrossRef
7.
go back to reference Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589–600.CrossRef Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589–600.CrossRef
8.
go back to reference Kim DH, Kim SB. Hepatic failure by spontaneous reactivation of hepatitis B virus without a trigger factor in a patient with anti-HBs. Case Rep Gastroenterol. 2018;12:286–91.CrossRef Kim DH, Kim SB. Hepatic failure by spontaneous reactivation of hepatitis B virus without a trigger factor in a patient with anti-HBs. Case Rep Gastroenterol. 2018;12:286–91.CrossRef
9.
go back to reference Inoue J, Ueno Y, Kogure T, et al. Analysis of the full-length genome of hepatitis B virus in the serum and cerebrospinal fluid of a patient with acute hepatitis B and transverse myelitis. J Clin Virol. 2008;41:301–4.CrossRef Inoue J, Ueno Y, Kogure T, et al. Analysis of the full-length genome of hepatitis B virus in the serum and cerebrospinal fluid of a patient with acute hepatitis B and transverse myelitis. J Clin Virol. 2008;41:301–4.CrossRef
10.
go back to reference Thedja MD, Roni M, Harahap AR, et al. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608–14.CrossRef Thedja MD, Roni M, Harahap AR, et al. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608–14.CrossRef
11.
go back to reference Bhattacharya H, Bhattacharya D, Roy S, et al. Occult hepatitis B infection among individuals belonging to the aboriginal Nicobarese tribe of India. J Infect Dev Ctries. 2014;8:1630–5.CrossRef Bhattacharya H, Bhattacharya D, Roy S, et al. Occult hepatitis B infection among individuals belonging to the aboriginal Nicobarese tribe of India. J Infect Dev Ctries. 2014;8:1630–5.CrossRef
12.
go back to reference Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823–33.CrossRef Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823–33.CrossRef
13.
go back to reference Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.CrossRef Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–9.CrossRef
14.
go back to reference Pollicino T, Cacciola I, Saffioti F, et al. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61:408–17.CrossRef Pollicino T, Cacciola I, Saffioti F, et al. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61:408–17.CrossRef
15.
go back to reference Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64:S4–S16.CrossRef Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64:S4–S16.CrossRef
16.
go back to reference Ito K, Qin Y, Guarnieri M, et al. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol. 2010;84:12850–61.CrossRef Ito K, Qin Y, Guarnieri M, et al. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol. 2010;84:12850–61.CrossRef
17.
go back to reference Ie SI, Thedja MD, Roni M, et al. Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors. Virol J. 2010;7:326.CrossRef Ie SI, Thedja MD, Roni M, et al. Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors. Virol J. 2010;7:326.CrossRef
18.
go back to reference Colson P, Borentain P, Coso D, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015;484:354–63.CrossRef Colson P, Borentain P, Coso D, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015;484:354–63.CrossRef
19.
go back to reference Okamoto H, Imai M, Tsuda F, et al. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987;61:3030–4.CrossRef Okamoto H, Imai M, Tsuda F, et al. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987;61:3030–4.CrossRef
20.
go back to reference Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13:344–58.CrossRef Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13:344–58.CrossRef
21.
go back to reference Inuzuka T, Ueda Y, Arasawa S, et al. Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Sci Rep. 2018;8:18070.CrossRef Inuzuka T, Ueda Y, Arasawa S, et al. Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Sci Rep. 2018;8:18070.CrossRef
22.
go back to reference Alexopoulou A, Dourakis SP, Pandelidaki H, et al. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol. 2006;78:1043–6.CrossRef Alexopoulou A, Dourakis SP, Pandelidaki H, et al. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol. 2006;78:1043–6.CrossRef
23.
go back to reference Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011;83:412–8.CrossRef Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011;83:412–8.CrossRef
24.
go back to reference Inoue J, Ueno Y, Wakui Y, et al. Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J Infect Dis. 2011;204:1017–25.CrossRef Inoue J, Ueno Y, Wakui Y, et al. Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J Infect Dis. 2011;204:1017–25.CrossRef
Metadata
Title
Spontaneous reactivation of hepatitis B virus with S gene mutations in an elderly patient with diabetic nephropathy
Authors
Noriyuki Obara
Jun Inoue
Hiroyuki Endo
Eiji Kakazu
Masashi Ninomiya
Tomoaki Iwata
Akitoshi Sano
Mio Tsuruoka
Atsushi Masamune
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 5/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01149-w

Other articles of this Issue 5/2020

Clinical Journal of Gastroenterology 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.